I agree. I read up on PATH. Seems that they were FDA approved recently for their migraine patch, ZECUITY, but the stock dropped because they were trying to launch their drug alone. Now there seems to be a new production facility and pending news of a partnership/bid war. (if true, that's going to lift this stock fast)
Earnings release is Monday. I wouldn't expect anything but mediocre results for financials, but the money is in the future outlook. Apparently they've been sending samples to doctors before ramping up their production and sales. I'm hoping for an announcement of a Glaxo partnership.